NBIX · Company research
Neurocrine Biosciences Inc (NBIX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
30records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo Finance Australia | Neurocrine Biosciences, Inc. (NBIX) Stock forecasts Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 17, 2026 | neutral | 0 | 0.6 |
| Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings - Yahoo Finance | Neurocrine Biosciences (NBIX) Stock Trades Below Fair Value On Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| More than 2,800 health events trace how a rare disorder's care needs shift with age - Stock Titan | More than 2,800 health events trace how a rare disorder's care needs shift with age Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) - Stock Titan | JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX) Stock Titan | View source ↗ | Stock Titan | Oct 15, 2026 | neutral | 0 | 0.6 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight | Over 200 companies are advancing next-generation obesity therapies, with more than 30 drugs in late-stage development and 180+ in mid and early stages. Key players include Eli Lilly, Novo Nordisk, Viking Therapeutics, and Roche, developing innovative mechanisms like dual GLP-1/GIP receptor agonists and triple hormone receptor agonists. Recent approvals include Novo Nordisk's oral Wegovy formulation and Eli Lilly's orforglipron, while multiple Phase III trials show promising weight loss results. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 0.875 | 1 |
| Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Australia | Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term | Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top value stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company features an attractive forward P/E ratio of 14.86, a Value Style Score of B, and has seen upward earnings estimate revisions with a consensus estimate of $9.09 per share for fiscal 2026, along with an average earnings surprise of +13.6%. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term | Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top value stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company features an attractive forward P/E ratio of 14.86, a Value Style Score of B, and has seen upward earnings estimate revisions with a consensus estimate of $9.09 per share for fiscal 2026, along with an average earnings surprise of +13.6%. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance Singapore | Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history Yahoo Finance Singapore | View source ↗ | Yahoo Finance Singapore | Oct 13, 2026 | neutral | 0 | 0.6 |
| NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? | A comparison of two Medical-Drugs sector stocks reveals that Neurocrine Biosciences (NBIX) presents a better value opportunity than Sandoz Group AG (SDZNY). Both stocks hold a Zacks Rank #2 (Buy) with positive earnings outlooks, but NBIX's superior valuation metrics—including a lower forward P/E ratio of 15.55 versus SDZNY's 20.49, and a PEG ratio of 0.53 compared to 1.69—earned it a Value grade of B versus SDZNY's C grade. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? | A comparison of two Medical-Drugs sector stocks reveals that Neurocrine Biosciences (NBIX) presents a better value opportunity than Sandoz Group AG (SDZNY). Both stocks hold a Zacks Rank #2 (Buy) with positive earnings outlooks, but NBIX's superior valuation metrics—including a lower forward P/E ratio of 15.55 versus SDZNY's 20.49, and a PEG ratio of 0.53 compared to 1.69—earned it a Value grade of B versus SDZNY's C grade. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.5 | 1 |
| NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? - Yahoo Finance | NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term | Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top growth stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasting year-over-year earnings growth of 42.3% for fiscal 2026, with a consensus earnings estimate of $9.09 per share and an average earnings surprise of +13.6%. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term | Neurocrine Biosciences (NBIX), a neuroscience-focused biopharmaceutical company, has been identified as a top growth stock with a Zacks Rank #2 (Buy) rating and a VGM Score of A. The company is forecasting year-over-year earnings growth of 42.3% for fiscal 2026, with a consensus earnings estimate of $9.09 per share and an average earnings surprise of +13.6%. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. - Stock Titan | Neurocrine is set to release Q3 results at 1 p.m. Pacific on Nov. 2, then host a call. Stock Titan | View source ↗ | Stock Titan | Oct 12, 2026 | neutral | 0 | 0.6 |
| Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Neurocrine Biosciences, Inc. (NBIX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history - Yahoo Finance UK | Neurocrine Biosciences, Inc. (NBIX) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 9, 2026 | neutral | 0 | 0.6 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| 4 CNS Drug Stocks Worth Watching This World Mental Health Day | Four central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Neurocrine Biosciences (NasdaqGS:NBIX) Stock Forecast & Analyst Predictions - Simply Wall Street | Neurocrine Biosciences (NasdaqGS:NBIX) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 9, 2026 | neutral | 0 | 0.6 |
| A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. - Stock Titan | A joint trust holds 50,146 shares for Neurocrine Biosciences (NBIX) medical chief Eiry Roberts. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Studies will track real-world use of a treatment for intense hunger and hear from caregivers. - Stock Titan | Studies will track real-world use of a treatment for intense hunger and hear from caregivers. Stock Titan | View source ↗ | Stock Titan | Sep 30, 2026 | neutral | 0 | 0.6 |
| After 26 years at Eli Lilly, Eiry Roberts returns to Neurocrine as its chief medical officer. - Stock Titan | After 26 years at Eli Lilly, Eiry Roberts returns to Neurocrine as its chief medical officer. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? - Yahoo Finance | Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 20, 2026 | neutral | 0 | 0.6 |
| NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? - Zacks Investment Research | NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell? Zacks Investment Research | View source ↗ | Zacks Investment Research | Aug 17, 2026 | neutral | 0 | 0.6 |
| NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings - Stocktwits | NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings Stocktwits | View source ↗ | Stocktwits | Aug 12, 2026 | neutral | 0 | 0.6 |
| Why Neurocrine Biosciences (NBIX) Stock Is Down Today - Quiver Quantitative | Why Neurocrine Biosciences (NBIX) Stock Is Down Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus - Simply Wall Street | Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus Simply Wall Street | View source ↗ | Simply Wall Street | Aug 1, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.